FDA Opens Its Review Dossiers to Foreign Regulators
FDA's Global Reliance Disclosure Program shares review dossiers with foreign regulators; UPS acquires Smartways Logistics; Cognizant targets sub-seven-day therapy starts with AI agents.
TAG P-4283 · 641 words on the filing

Summary of findings
- FDA launched the Global Reliance Disclosure Program on November 17, 2026, opening with a tentative approval of lenacapavir.
- GRDP expands to all NDAs and BLAs in January 2027; an expedited pathway for already-approved products follows in early 2027.
- UPS agreed to acquire Smartways Logistics, whose 350+ drivers form the largest dedicated healthcare courier network in Australia and New Zealand; close expected in H1 2027.
- Cognizant Patient Hub Operations, built on NVIDIA computing, aims to cut prescription-to-therapy time from about 30 days to under seven.
- The Cognizant offering launches with five AI agents covering inquiry, routing, translation, handoff and call summarization.
The FDA will let companies pass its minimally redacted approval packages to regulators outside the United States, under a Global Reliance Disclosure Program launched November 17, 2026. Foreign authorities can then rely on the FDA's scientific and regulatory assessments instead of running duplicate reviews — while keeping final authority over their own decisions.
The announcement landed alongside a tentative approval for lenacapavir, indicated for HIV prevention and treatment. That pairing was deliberate. For now, the program covers only tentative approvals under the President's Emergency Plan for AIDS Relief, and it excludes tentatively approved generics. The FDA intends to widen the aperture in January 2027, when all new drug applications and biologics license applications become eligible. An early-2027 pathway will expedite requests for packages on products already approved or licensed in the US.
What problem is the FDA actually solving?
The agency's own framing is capacity. According to the FDA, patients in many parts of the world wait months or years longer than necessary because national regulators lack the resources to finish independent reviews. Sharing the FDA's work, the argument goes, shortens that timeline.
That claim is plausible but untested at scale. The program's initial scope — PEPFAR tentative approvals minus generics — is narrow enough that the January expansion, not this launch, is the real test. How many regulators will actually accept reliance, and on what terms, remains unstated.
UPS buys a dedicated healthcare courier in Oceania
UPS has agreed to acquire Smartways Logistics, a healthcare logistics provider serving Australia and New Zealand, in a deal the company says will strengthen UPS Healthcare's time-critical transportation in the region. Financial terms were not disclosed. Closing is expected in the first half of 2027, subject to regulatory reviews and approvals.
Smartways brings a concrete asset base:
- Next-flight-out, same-day ground and overnight transportation
- Reverse logistics and 3PL services
- Clients across medical device, pharmaceutical, clinical trial and radiopharmaceutical sectors
- More than 350 drivers, which Smartways calls the region's largest dedicated healthcare network
UPS positioned the acquisition within its broader Asia-Pacific healthcare buildout, citing its recently opened Clark hub in the Philippines and continuing cold chain investments. A purchase price would have made the regional commitment measurable; its absence leaves the strategic intent as the only firm detail.
Can AI agents cut prescription-to-therapy time from 30 days to seven?
Cognizant introduced Cognizant Patient Hub Operations on November 18, an offering built on NVIDIA accelerated computing that pairs AI agents with human specialists. The target is aggressive: reduce the typical time from prescription to therapy start from roughly 30 days to under seven. Cognizant says that figure rests on its own analysis of current patient access workflows and case volumes — an in-house benchmark, not an independent one.
The structural change is sequencing. Coverage confirmation, insurer authorization and financial assistance normally run one after another. The offering starts all three at intake, so cases move in parallel rather than in series.
Where do the humans stay in the loop?
Cognizant's agents handle patient conversations and routine administrative work, drawing on each program's prescribing information, standard operating procedures and payer rules. Specialists review, approve or escalate AI-prepared actions, and Cognizant says humans keep the final say on any decision governed by regulation.
At launch, five agents cover patient inquiry, intelligent routing, translation, human handoff and call summarization. The compliance architecture reads sensibly on paper. Whether a sub-seven-day turnaround survives contact with payer variability and high-volume escalations is a question the launch materials do not answer.
Three moves, one direction: regulators, couriers and IT vendors are all compressing the distance between approval and patient. Each comes with a 2027 date attached — the GRDP expansion in January, the Smartways close in the first half. The market will not wait long for evidence.
via fda.gov (Original)
More from Rebecca Stone
Show full bio
Staff writer covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.
18 articles
Linked filings
- E-4696
- P-6323
- K-6477
- T-2815
- E-9124